Purdue Pharma announced today that it acquired SpineThera and a dexamethasone epidural product designed to treat low back pain. SpineThera’s SX600 therapy features tiny, biodegradable microspheres which enable sustained-release of dexamethasone. “We are pleased to partner with SpineThera to support further development of its novel steroid product for epidural injection for patients who suffer from […]
Fresenius cleared to jilt Akorn, court rules
The Delaware Chancery Court ruled this week that it can’t force Fresenius (ETR:FRE) to follow through with its $4.75 billion merger with Akorn (NSDQ:AKRX). The deal was designed to help Fresenius move into new dosage forms and therapeutic areas, including ophthalmic drugs, ear drops, nasal sprays and respiratory drugs. But Fresenius walked away from the deal in April, […]
Johnson & Johnson closes $2B LifeScan sale
Johnson & Johnson (NYSE:JNJ) said today that closed the $2.1 billion sale of its LifeScan blood glucose monitoring subsidiary to private equity player Platinum Equity. The sale is part of the New Brunswick, N.J.-based healthcare conglomerate’s move to get out of the device end of the diabetes business. Early last year J&J announced a strategic review of the LifeScan, Animas […]
Smiths Medical spikes merger talks with ICU Medical
Smiths Group (LON:SMIN) said yesterday that it’s spiking merger talks with ICU Medical (NSDQ:ICUI) after rejecting a nearly $4 billion offer earlier this month. The British company and San Clemente, Calif.-based ICU revealed negotiations in May about a possible union with Smiths Medical. Smiths, said to be eyeing the exit door last month, reportedly rejected a cash-and-stock offer […]
PCI Pharma Services to buy Sherpa Clinical Packaging
PCI Pharma Services has agreed to acquire clinical supply services provider Sherpa Clinical Packaging, the companies announced today. Financial terms of the deal were not disclosed. San Diego–based Sherpa is a provider of clinical trial material management services for clinical studies phases I through IV, with expertise in packaging, labeling, distribution, storage and returns and […]
Report: Smiths may abandon talks of merger with ICU Medical
Smiths Group (LON:SMIN) may walk away from talks of a $9 billion merger of its healthcare division with ICU Medical (NSDQ:ICUI), Sky News reported this week. The two groups began talks more than two months ago, but Smiths is reportedly leaning towards a decision to abandon negotiations. Talks of a potential merger have sparked interest by Baxter to pursue […]
United Therapeutics $216m deal for SteadyMed clears HRS Act waiting period
United Therapeutics (NSDQ:UTHR) said today that it stepped closer to completing its $216 million acquisition of SteadyMed (NSDQ:STDY) after terminating the the HSR Act waiting period. The merger combines two companies that were in court as recently as last November, fighting over patents covering treprostinil, the active ingredient in both companies’ lead products. In the deal, United Therapeutics will pay […]
CeQur acquires wearable insulin delivery device
CeQur said today that it acquired a wearable, on-demand insulin delivery system from Johnson & Johnson‘s (NYSE:JNJ) Calibra Medical for an undisclosed amount. The Calibra device is designed to dose rapid-acting, mealtime insulin for people with Type II diabetes. In a 278-person study, use of the Calibra device resulted in higher ease-of-use and patient satisfaction […]
Gerresheimer to acquire Sensile Medical and its drug-delivery tech
Updated 7/13 to include the deal’s financial details. Gerresheimer plans to acquire Swiss medical technology company Sensile Medical and its array of liquid drug delivery devices. The buyout is a perfect fit in Gerresheimer’s portfolio, the company explained, since it will boost Gerresheimer’s drug delivery offerings and add new digital and electronic capabilities into the mix. […]
Catalent expands early-phase development skills with $139m Juniper buyout
Catalent (NYSE:CTLT) said today that it inked a $139 million deal to acquire Juniper Pharmaceuticals (NSDQ:JNP) and its early-stage product development services. The company noted that its Juniper acquisition, set at $11.50 per share, will complement Catalent’s formulation development offerings, bioavailability solutions and clinical-scale oral dose manufacturing capabilities. “Juniper’s proven solutions and capabilities will further support […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 13
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn